New Report Forecasts the Outlook for Medicated Skin Care in Mexico to 2011

Business Wire,  May 2, 2008  

• E-mail
• Print
• Link

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c90527) has announced the addition of Euromonitor International's new report: Medicated Skin Care in Mexico to their offering.

Our Medicated Skin Care in Mexico report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data (2001-2006), allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market - be they new product developments, distribution or pricing issues. Forecasts to 2011 illustrate how the market is set to change.

Product coverage: acne treatments, antipruritics, topical germicidals/antiseptics, topical allergy remedies/antihistamines, topical antifungals, vaginal antifungals, antiparasitics/lice (head and body) treatments, medicated shampoos, hair loss treatments, lip care treatments, haemorrhoid treatments, child-specific medicated skin care, nappy (diaper) rash treatments

Data coverage: market sizes (historic and forecasts), company shares and brand shares

Why buy this report?

* Get a detailed picture of the medicated skin care industry

* Identify factors driving change

* Understand the competitive environment, the market's major players and leading brands

* Use five-year forecasts to assess how the market is predicted to develop

Executive Summary from OTC Healthcare in Mexico

Generics affect the dynamism of OTC healthcare sales

OTC healthcare is highly competitive and became more so with the recent emergence of generics, through Farmacias de Similares, a chain of pharmacies that manufactures similares or generic versions of brands. The government exerts some control over these players. However, legislation is still vague and the effect that this competition is having on OTC healthcare is notable. In addition, the ease with which most people can buy under-the-counter drugs puts OTC healthcare in a very difficult situation.

Seguro Popular influencing OTC healthcare

Pharmaceutical sales became more complex since the approval of Seguro Popular, a public policy that provides low-cost medical services to people currently excluded from government-provided healthcare. The Seguro Popular initiative targets close to half of the Mexican population. One aspect of this service is that both prescription and OTC healthcare provided through the initiative is generic, rather than branded. Domestic manufacturers generally supply generics to the government, rather than the multinationals that dominate OTC healthcare in Mexico.

Pharmaceutical players struggle to maintain share

Many factors affected the local pharmaceutical industry, particularly the introduction of generics. The large laboratories are suffering from competition from generics, particularly via Farmacias Similares. A large quantity of generics was offered at low prices by the government through social programmes. Consequently, OTC healthcare lost competitiveness and price reductions were inevitable.

Success is based on lobbying doctors

Since the mass media advertising of OTC healthcare is restricted by the government, players compete through an extensive sales force. Success depends primarily on their ability to win the support of doctors and pharmacy owners. While brand loyalty is high, it generally develops as the result of an initial recommendation from a doctor or pharmacist.

Socio-economic trends favour OTC healthcare over the forecast period

Despite the negative performance of branded OTC healthcare in 2006, prospects point towards a recovery during the forecast period. The general economic situation, with a middle-income group improving their purchasing power and a gradually aging population, will affect sales positively. More people will be able to afford branded OTC healthcare in the near future. In addition, responsible self-medication is projected to increase for niche OTC healthcare, as firms invest in growing sales through educational campaigns. Overall, the negative effect of generics on value sales will be offset in most product areas by an increase in demand. This will be driven either by consumers switching from traditional remedies to OTC healthcare or by changing environmental and demographic trends.

Companies Mentioned:
Wyeth SA de CV
Procter & Gamble de Mexico SA de CV
Pfizer SA de CV
Novartis Farmaceutica SA de CV
Merck-Mexico SA
Laboratorios Liomont SA de CV
Boehringer Ingelheim Promeco SA de CV
Bayer de Mexico SA de CV
GlaxoSmithKline Mexico SA de CV

For more information visit http://www.researchandmarkets.com/reports/c90527

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning